Cargando…
Comment on Herring et al. The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations. Cells 2022, 11, 1044
This commentary is written in response to the recent article from Herring et al., discussing the eradication of the offensive term “retardation” from gene nomenclature. We discuss the work of the HUGO (Human Genome Organisation) Gene Nomenclature Committee (HGNC) and outline the steps already taken...
Autor principal: | Bruford, Elspeth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221639/ https://www.ncbi.nlm.nih.gov/pubmed/35741066 http://dx.doi.org/10.3390/cells11121937 |
Ejemplares similares
-
The Use of “Retardation” in FRAXA, FMRP, FMR1 and Other Designations
por: Herring, Jonathan, et al.
Publicado: (2022) -
Ovarian dysfunction and FMR1 alleles in a large Italian family with POF and FRAXA disorders: case report
por: Miano, Maria Giuseppina, et al.
Publicado: (2007) -
Comment on Weitzman et al. Resistance to Antimalarial Monotherapy Is Cyclic. J. Clin. Med. 2022, 11, 781
por: van der Pluijm, Rob W., et al.
Publicado: (2022) -
Comment on Sah et al. Monkeypox and Its Possible Sexual Transmission: Where Are We Now with Its Evidence? Pathogens 2022, 11, 924
por: Vera, Milagros Nilda, et al.
Publicado: (2022) -
Untapped Potential for Female Patients? Comment on Lucà et al. Update on Management of Cardiovascular Diseases in Women. J. Clin. Med. 2022, 11, 1176
por: Kielb, Julia, et al.
Publicado: (2022)